Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1589975 | 0.84 | ALDH1A1 (0.44) | CYP3A4MAPTBRD4ALDH1A1KDM4E | |
| SCHEMBL7277184 | 0.78 | MAPT (0.42) | CYP3A4MAPTBRD4ALDH1A1KDM4E | |
| SCHEMBL7277175 | 0.78 | MAPT (0.42) | CYP3A4MAPTBRD4ALDH1A1KDM4E | |
| SCHEMBL7277292 | 0.78 | MAPT (0.42) | CYP3A4MAPTBRD4ALDH1A1KDM4E | |
| SCHEMBL10970757 | 0.76 | GAA (0.48) | MAPTALDH1A1KDM4EMAOAMAOB | |
| SCHEMBL10711789 | 0.76 | FDPS (0.41) | CYP3A4MAPTBRD4ALDH1A1KDM4E | |
| SCHEMBL10711798 | 0.76 | FDPS (0.41) | CYP3A4MAPTBRD4ALDH1A1KDM4E | |
| SCHEMBL13556358 | 0.73 | CYP3A4 (0.54) | CYP3A4MAPTBRD4ALDH1A1KDM4E | |
| SCHEMBL30666906 | 0.72 | CYP3A4 (0.52) | CYP3A4MAPTBRD4ALDH1A1KDM4E | |
| SCHEMBL11886578 | 0.71 | ERN1 (0.42) | CYP3A4MAPTALDH1A1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833156-B2 | Heterocyclic compounds as pad inhibitors | Jubilant Epipad LLC (US) | 2023-12-05 | — | — | US | disclosed |
| US-20120270863-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2012-10-25 | — | — | US | disclosed |
| EP-0199393-B1 | INDENE AND NAPHTHALENE DERIVATIVES | AKZO N.V. (NL) | 1988-12-07 | — | — | EP | disclosed |
| US-4705782-A | Indene and naphthalene derivatives | AKZO N.V. (NL) | 1987-11-10 | — | — | US | disclosed |
| EP-0199393-A1 | Indene and naphthalene derivatives | AKZO N.V. (NL) | 1986-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270863-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, COL2A1 | CYP3A4 4681/4885MAPT 4668/4885BRD4 394/4885 |
| US-11833156-B2 | Heterocyclic compounds as pad inhibitors | PADI4, PADI2, PADI1 | CYP3A4 22/4885MAPT 3841/4885BRD4 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.